Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype

Jan H. Beumer(Johns Hopkins University), Olaf van Tellingen(Dutch Cancer Society), Mariët Ouwehand, Jos H. Beijnen(The Netherlands Cancer Institute), N. Franke(Princess Máxima Center), Jan H.M. Schellens(Utrecht University), Tessa Buckle(Leiden University Medical Center), Luis López Lázaro(Dr. Reddy's Laboratories (Switzerland))
Investigational New Drugs
April 5, 2006
10.1007/s10637-006-7773-9
Cited by 17

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884